Edinburg, TX (January 26, 2022) – DHR Health Institute for Research and Development is currently offering long-acting monoclonal antibody treatment to PREVENT COVID-19 in high-risk patients. This is the only treatment currently available to prevent infection by the Omicron variant of SARS-CoV-2…the virus that causes COVID-19.
On December 8, 2021, the U.S. Food and Drug Administration issued an Emergency Use Authorization allowing the use of AstraZeneca’s long-acting antibody EVUSHELDTM to be used for prevention of COVID-19 in subjects 12 years and older with moderate to severe immunocompromised status before exposure to the virus.
“The majority of the patients who are currently hospitalized with severe COVID-19 are those who are unvaccinated, and those who are vaccinated, but have a compromised immune system” said Sohail Rao, MD, MA, DPhil, President and CEO, DHR Health Institute for Research & Development. “Given that Omicron is the dominant variant which is responsible for the current spike in COVID-19 cases in the US and globally, EVUSHELDTM is the only antibody that can offer long-term protection against this variant in patients with weakened immune system”
If you are a patient who is receiving chemotherapy for cancer, immunosuppressive drugs following transplantation or for conditions such as rheumatoid arthritis and lupus, etc., consider treatment with this long-acting monoclonal antibody. Treatment with this long-acting antibody will provide patients with protection against SARS-CoV-2 (including its Omicron variant) for up to 6-9 months. In the last few weeks, we have treated over 50 patients at DHR Health with this monoclonal antibody with a very satisfactory outcome.
If you or your patient is interested to receive this treatment or need to discuss their condition further, please call 956-342-4896 or download the contact information by using this QR Code:
About DHR Health Institute for Research & Development
DHR Health Institute for Research & Development, is a nonprofit organized under the Federal Internal Revenue Service Code 501(c)(3). As the largest and the most comprehensive entity conducting translational and clinical research in South Texas, DHR Health Institute for Research and Development leads the way in bringing innovative, state-of-the-art advanced treatment options for our patients in the community. DHR Health Institute for Research and Development provides oversight of translational and clinical research in DHR Health, DHR Health Brownsville, Starr County Memorial Hospital, and all clinics under Renaissance Medical Foundation. To learn more, visit this website at www.dhrresearch.org.
About DHR Health
DHR Health was founded in 1997 to help over 1.4 million residents resolve limited health care access challenges in a community that lacked public and county hospitals. Today, it is a modern, 600+ bed full-service health system serving over 280,000 patients annually, with 5500+ employees, over 650 physicians and more than 1,400 nurses dedicated to offering a full continuum of care in over 70 different specialties and subspecialties. As the only Trauma Level I facility in South Texas, DHR Health proudly boasts the best specialty care in the region, a 24/7 functioning level-one trauma center, a robust clinical research division, and developing graduate medical education programs. DHR Health has revolutionized the health care landscape of the Rio Grande Valley and continues to raise the standard of care and transform the health care delivery model for the benefit all local residents. To learn more, visit this website at www.dhrhealth.com
